| Literature DB >> 23853701 |
Ibrahimu Mdala1, Ingar Olsen, Anne D Haffajee, Sigmund S Socransky, Birgitte Freiesleben de Blasio, Magne Thoresen.
Abstract
AIM: To follow changes (over 2 years) in subgingival bacterial counts of five microbial complexes including health-related Actinomyces spp. in deeper pockets (≥5 mm) after periodontal treatments.Entities:
Keywords: NB GEE; antibiotics; chronic periodontitis; fractional response methods; microbiota; multilevel analysis; periodontal therapy
Year: 2013 PMID: 23853701 PMCID: PMC3708352 DOI: 10.3402/jom.v5i0.20939
Source DB: PubMed Journal: J Oral Microbiol ISSN: 2000-2297 Impact factor: 5.474
Baseline characteristics of the study subjects
| Treatments | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| |
|
| 26 | 19 | 25 | 22 | 28 | 26 | 25 | 25 | 0.44 |
| Age (years) | 50±12 | 54±12 | 54±11 | 54±9 | 53±7 | 50±10 | 50±10 | 55±12 | 0.39 |
| Americans ( | 14 | 8 | 11 | 10 | 15 | 13 | 12 | 12 | 0.99 |
| Females ( | 13 | 8 | 13 | 9 | 15 | 10 | 15 | 13 | 0.78 |
|
| |||||||||
| Smoking status – number (%) | |||||||||
| Current smoker | 9 (35) | 8 (42) | 11 (44) | 7 (32) | 14 (50) | 10 (38) | 8 (32) | 11 (44) | 0.91 |
|
| |||||||||
| Mean log counts | |||||||||
| Red | 13.7±2.4 | 13.5±2.9 | 13.2±3.1 | 13.7±2.6 | 13.4±3.2 | 13.7±2.7 | 13.6±2.1 | 13.6±2.1 | 0.55 |
| Orange | 14.7±1.7 | 14.7±1.8 | 15.0±1.5 | 14.6±1.9 | 14.5±2.0 | 14.8±1.9 | 14.7±1.9 | 14.9±1.5 | 0.41 |
|
| 13.2±2.7 | 13.8±1.7 | 13.4±2.8 | 13.4±2.9 | 13.5±2.3 | 13.3±2.9 | 13.5±2.2 | 13.6±2.4 | 0.43 |
| Yellow | 12.2±2.9 | 10.9±3.5 | 11.5±3.3 | 11.6±3.0 | 11.8±3.2 | 11.8±3.0 | 12.3±2.5 | 12.0±2.5 | 0.52 |
| Purple | 12.2±3.0 | 12.6±2.3 | 12.7±2.3 | 12.1±3.1 | 12.2±3.0 | 11.9±3.2 | 12.3±2.6 | 12.6±2.7 | 0.16 |
| Green | 13.4±2.4 | 13.9±1.5 | 13.4±2.4 | 13.4±2.5 | 13.3±2.3 | 13.3±2.3 | 13.5±1.9 | 13.5±2.4 | 0.31 |
|
| |||||||||
| Percentage of sites with | |||||||||
| Plaque | 23.6 | 37.5 | 26.8 | 32.4 | 336.6 | 27.1 | 32.8 | 37.8 | |
| Gingival redness | 33.5 | 34.3 | 33.9 | 32.6 | 38.3 | 33.5 | 27.8 | 40.0 | |
| Bleeding on probing | 50.0 | 34.9 | 32.6 | 41.9 | 32.3 | 26.2 | 44.4 | 37.2 | |
| Mean PD (mm) | 6.4±1.3 | 6.6±1.8 | 6.4±1.3 | 6.5±1.3 | 6.8±1.8 | 6.5±1.5 | 6.5±1.3 | 6.6±1.6 | 0.61 |
| Mean CAL (mm) | 6.0±2.4 | 5.9±2.5 | 6.3±2.0 | 6.0±1.8 | 6.7±2.3 | 6.9±2.3 | 6.0±1.7 | 6.7±2.5 | 0.29 |
| Number of missing teeth | 6.6±5.6 | 6.8±5.2 | 7.3±4.7 | 7.8±4.8 | 6.6±5.6 | 7.3±5.8 | 7.9±4.5 | 8.2±5.1 | 0.82 |
The eight treatments were:
1. Scaling and root planing (SRP).
2. SRP+surgery (SURG), systemic amoxicillin (AMOX)+metronidazole (MET).
3. SRP+SURG + locally delivered tetracycline (TET).
4. SRP+SURG.
5. SRP+systemic AMOX+MET and local TET.
6. SRP+systemic AMOX+MET.
7. SRP+locally delivered TET.
8. SRP+SURG+AMOX+MET+locally delivered TET.
Plus/minus values are mean±standard deviations.
There were no significant baseline differences between patients who were in the control group (SRP) and those receiving other treatments as evidenced by the large p-values. Box-plots for the mean distribution of the natural log counts of Actinomyces and red, orange, yellow, purple, and green complexes are given in Figs. 1A, 2A, 3A, S1A, S2A, and S3A, respectively.
IRR† estimates and confidence intervals for Actinomyces counts after adjusting for baseline counts in sites that had an initial PD≥5 mm from the GEE NB model using the exchangeable correlation structure in Stata
| Part (c) Comparison made to counts after 3 months | |||||
|---|---|---|---|---|---|
|
| |||||
| (b) IRR: 3 months | 6 months | 12 months | 18 months | 24 months | |
|
| |||||
| Treatment effect on | Marginal effects | IRR | IRR | IRR | IRR |
| (a) Reference treatment: SRP. | 1.48 (0.69, 3.15) | 1.43 (0.74, 2.77) | 1.42 (0.54, 3.78) | 1.06 (0.44, 2.54) | |
|
| |||||
| Compared with SRP | |||||
| SURG+AMOX+MET | 0.83 (0.39, 1.78) | 1.03 (0.44, 2.44) | 1.44 (0.64, 3.19) | 1.26 (0.44, 3.60) | 1.69 (0.65, 4.39) |
| SURG+TET | 1.09 (0.51, 2.35) | 0.95 (0.40, 2.23) | 1.19 (0.53, 2.66) | 1.07 (0.37, 3.06) | 1.45 (0.54, 3.86) |
| SURG | 0.84 (0.40, 1.77) | 1.37 (0.60, 3.12) | 1.50 (0.71, 3.20) | 1.06 (0.38, 2.95) | 1.53 (0.58, 3.99) |
| AMOX+MET+TET | 0.83 (0.39, 1.77) | 1.28 (0.55, 2.95) | 1.34 (0.63, 2.86) | 1.40 (0.49, 4.03) | 0.96 (0.37, 2.46) |
| AMOX+MET | 1.15 (0.55, 2.42) | 0.90 (0.39, 2.06) | 0.90 (0.39, 2.07) | 0.91 (0.31, 2.64) | 1.09 (0.39, 3.03) |
| TET | 0.94 (0.42, 2.09) | 1.05 (0.45, 2.46) | 0.91 (0.40, 2.05) | 0.86 (0.29, 2.53) | 1.31 (0.46, 3.70) |
| SURG+AMOX+MET+TET | 1.35 (0.62, 2.92) | 0.93 (0.41, 2.09) | 1.00 (0.48, 2.11) | 0.86 (0.30, 2.45) | 1.18 (0.45, 3.11) |
There were no significant changes in counts of Actinomyces that were observed in all treatment groups compared to counts in the reference group, SRP.
Incidence rate ratio=exp (β).
SURG was performed 3 months after the baseline visit. Results shown at the 3-month study period were for SRP.
SURG=surgery; AMOX=amoxicillin; MET=metronidazole; TET=tetracycline; IRR=incidence rate ratios.
IRR† estimates and confidence intervals for orange complex counts after adjusting for baseline counts in sites that had an initial PD ≥5 mm from the GEE NB model using the exchangeable correlation structure in Stata
| Part (c) Comparison made to counts after 3 months | |||||
|---|---|---|---|---|---|
|
| |||||
| (b) IRR: 3 months | 6 months | 12 months | 18 months | 24 months | |
|
| |||||
| Treatment effect on orange complex counts | Marginal effects | IRR | IRR | IRR | IRR |
| (a) Reference treatment: SRP | |||||
| 0.90 (0.68, 1.18) | 0.89 (0.67, 1.19) | 0.82 (0.66, 1.02) | 1.02 (0.75, 1.37) | ||
|
| |||||
| Compared with SRP | |||||
| SURG+AMOX+MET | 0.90 (0.68, 1.18) | 1.04 (0.74, 1.46) | 1.09 (0.76, 1.58) | 1.39 (1.04, 1.88) | 0.97 (0.68, 1.39) |
| SURG+TET | 0.92 (0.70, 1.21) | 1.14 (0.77, 1.70) | 1.18 (0.82, 1.70) | 1.36 (0.97, 1.91) | 1.05 (0.71, 1.56) |
| SURG | 0.88 (0.62, 1.24) | 1.20 (0.76, 1.89) | 1.08 (0.71, 1.64) | 1.39 (0.90, 2.13) | 1.17 (0.77, 1.77) |
| AMOX+MET+TET | 1.01 (0.75, 1.38) | 0.95 (0.65, 1.41) | 1.01 (0.65, 1.59) | 1.19 (0.86, 1.65) | 1.02 (0.68, 1.53) |
| AMOX+MET | 0.89 (0.66, 1.20) | 1.17 (0.79, 1.73) | 1.14 (0.76, 1.70) | 1.27 (0.90, 1.78) | 1.09 (0.73, 1.63) |
| TET | 1.05 (0.76, 1.44) | 1.01 (0.63, 1.62) | 0.97 (0.66, 1.43) | 1.02 (0.71, 1.46) | 0.95 (0.62, 1.45) |
| SURG+AMOX+MET+TET | 0.94 (0.70, 1.25) | 0.94 (0.67, 1.31) | 1.01 (0.71, 1.44) | 1.25 (0.86, 1.81) | 0.98 (0.68, 1.41) |
There were no significant reductions in orange complex counts that were observed in all treatment groups compared to SRP.
Incidence rate ratio=exp (β).
SURG was performed 3 months after the baseline visit. Results shown at the 3-month study period were for SRP.
Significant results at α=0.05.
Significant results at α=0.01.
SURG=surgery; AMOX=amoxicillin; MET=metronidazole; TET=tetracycline; IRR=incidence rate ratios.
IRR† estimates and confidence intervals for red complex counts after adjusting for baseline counts in sites that had an initial PD ≥5 mm from the GEE NB model using the exchangeable correlation structure in Stata
| Part (c) Comparison made to counts after 3 months | |||||
|---|---|---|---|---|---|
|
| |||||
| (b) IRR: 3 months | 6 months | 12 months | 18 months | 24 months | |
|
| |||||
| Treatment effect on red complex counts | Marginal effects | IRR | IRR | IRR | IRR |
| (a) Reference treatment: SRP | 1.30 (0.98, 1.71) | 1.37 (0.99, 1.90) | 1.36 (0.96, 1.93) | 1.77 (1.13, 2.78) | |
|
| |||||
| Compared with SRP | |||||
| SURG+AMOX+MET | 1.05 (0.61, 1.80) | 0.96 (0.58, 1.62) | 1.08 (0.61, 1.94) | 0.81 (0.47, 1.41) | 0.52 (0.24, 1.12) |
| SURG+TET | 0.95 (0.71, 1.29) | 0.92 (0.57, 1.48) | 0.87 (0.50, 1.53) | 0.96 (0.54, 1.69) | 0.72 (0.40, 1.32) |
| SURG | 1.06 (0.65, 1.70) | 1.01 (0.59, 1.73) | 0.79 (0.36, 1.75) | 0.96 (0.49, 1.90) | 0.88 (0.41, 1.90) |
| AMOX+MET+TET | 0.63 (0.43, 0.92) | 0.97 (0.62, 1,52) | 1.43 (0.84, 2.43) | 1.81 (1.07, 3.06) | 1.23 (0.58, 2.60) |
| AMOX+MET | 0.75 (0.50, 1.14) | 0.98 (0.59, 1.64) | 1.29 (0.56, 2.95) | 1.08 (0.54, 2.15) | 1.14 (0.51, 2.52) |
| TET | 0.96 (0.68, 1.35) | 0.85 (0.47, 1.53) | 1.08 (0.61, 1.91) | 1.19 (0.62, 2.30) | 1.01 (0.50, 2.04) |
| SURG+AMOX+MET+TET | 0.91 (0.60, 1.39) | 0.78 (0.43, 1.40) | 0.99 (0.56, 1.78) | 0.89 (0.46, 1.75) | 0.74 (0.34, 1.63) |
We observed a 3-month significant reduction in changes of the red complex counts from baseline of 37% in subjects treated with AMOX+MET+TET compared to SRP-treated subjects. No other significant reductions of the red complex counts in sites with severe chronic periodontitis were observed from all study treatments compared to SRP-treated subjects.
Incidence rate ratio=exp (β).
SURG was performed 3 months after the baseline visit. Results shown at the 3-month study period were for SRP.
Significant results at α=0.01.
SURG=surgery; AMOX=amoxicillin; MET=metronidazole; TET=tetracycline; IRR=incidence rate ratios.
Fig. 1Box-plot showing the median distribution of Actinomyces counts by treatment group at baseline. Treatments 1–8 are SRP, surgery (SURG)+AMOX+MET, SURG+TET, SURG, AMOX+MET+TET, AMOX+MET, TET, and SURG+AMOX+MET+TET, respectively. Minimal variations in the median distributions of the counts can be seen. The circles in the plot indicate outliers.
Fig. 2Changes in natural log counts of Actinomyces at each study time point from baseline. Study time points 1–6 correspond to baseline, 3, 6, 12, 18, and 24 months, respectively. Lower counts in all treatment groups can be seen at 3 months compared to baseline counts. Compared to the reference group SRP, subjects in the AMOX+MET+TET and TET groups had lesser counts between baseline and 3 months.
Fig. 3Box-plot showing the median distribution of the red complex counts by treatment at baseline. Treatments 1–8 are SRP, surgery (SURG)+AMOX+MET, SURG+TET, SURG, AMOX+MET+TET, AMOX+MET, TET, and SURG+AMOX+MET+TET, respectively. Lesser counts of the red complex were observed at baseline in the SURG+TET and SURG+AMOX+MET+TET-treated groups. The circles in the plot indicate outliers.
Fig. 4Changes in natural log counts of the red complex at each study time point from baseline. Study time points 1–6 correspond to baseline, 3, 6, 12, 18, and 24 months, respectively. Much lesser counts of the red complex were observed between baseline and 3 months in subjects who were treated with AMOX+MET+TET.
Fig. 5Box-plot showing the median distribution of orange complex counts by treatment at baseline. The treatments 1–8 are SRP, surgery (SURG)+AMOX+MET, SURG+TET, SURG, AMOX+MET+TET, AMOX+MET, TET, and SURG+AMOX+MET+TET, respectively. Again, minimal variations in the median distributions of the counts can be seen.
Fig. 6Changes in natural log counts of the orange complex at each study time point from baseline. Study time points 1–6 correspond to baseline, 3, 6, 12, 18, and 24 months, respectively. Subjects treated with surgery (SURG)+TET had lesser counts at 3 months.